| Literature DB >> 16451849 |
Abstract
As a growing applied science, nanotechnology has considerable global socioeconomic value, and the benefits afforded by nanoscale materials and processes are expected to have significant impacts on almost all industries and all areas of society. A diverse array of engineered nanoscale products and processes have emerged [e.g., carbon nanotubes, fullerene derivatives, and quantum dots (QDs)], with widespread applications in fields such as medicine, plastics, energy, electronics, and aerospace. With the nanotechnology economy estimated to be valued at dollar 1 trillion by 2012, the prevalence of these materials in society will be increasing, as will the likelihood of exposures. Importantly, the vastness and novelty of the nanotechnology frontier leave many areas unexplored, or underexplored, such as the potential adverse human health effects resulting from exposure to novel nanomaterials. It is within this context that the need for understanding the potentially harmful side effects of these materials becomes clear. The reviewed literature suggests several key points: Not all QDs are alike; engineered QDs cannot be considered a uniform group of substances. QD absorption, distribution, metabolism, excretion, and toxicity depend on multiple factors derived from both inherent physicochemical properties and environmental conditions; QD size, charge, concentration, outer coating bioactivity (capping material and functional groups), and oxidative, photolytic, and mechanical stability have each been implicated as determining factors in QD toxicity. Although they offer potentially invaluable societal benefits such as drug targeting and in vivo biomedical imaging, QDs may also pose risks to human health and the environment under certain conditions. Key words: environment, human health, nanomaterials, nanosized particles, nanotechnology, nanotoxicology, quantum dots, toxicology.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16451849 PMCID: PMC1367826 DOI: 10.1289/ehp.8284
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Figure 1QDs consist of a metalloid core and a cap/shell that shields the core and renders the QD bioavailable. The further addition of biocompatible coatings or functional groups can give the QD a desired bioactivity.
Review articles summary of QD types, exposure concentrations, experimental conditions, and observed toxicity.
| QD | Model | Exposure conditions/administration | QD concentration | Exposure duration | Toxicity | Reference |
|---|---|---|---|---|---|---|
| CdSe/ZnS–SSA | EL-4 cells | 1 × 106 cells/well | 0.1–0.4 mg/mL | 0–24 hr | Cytotoxic: 0.1 mg/mL altered cell growth; most cells nonviable at 0.4 mg/mL | |
| CdSe/ZnS–SSA | EL-4 cells | 200 μL cell suspension injected (iv) into mice | 0.1 mg/mL QDs per 5 × 107 cells | 2 hr to 7 days | No toxicity in mice | |
| CdSe/ZnS conjugates: NH2, OH, OH/COOH, H2/OH, MUA, COOH | WTK1 cells | 5 × 104 cells/mL | 1–2 μM | 12 hr | 2 μM QD–COOH induced DNA damage at 2 hr
| |
| CdSe/ZnS–MUA | Vero, HeLa, and primary human hepatocytes | 100 μL QDs/3 × 104 cells | 0–0.4 mg/mL | 24 hr | Cytotoxic: 0.2 mg/mL, Vero; 0.1 mg/mL, HeLa; 0.1 mg/mL, hepatocytes; | |
| CdTe | Rat pheochromocytoma cells, murine microglial cells | 1 × 105 cells/cm2 | 0.01–100 μg/mL | 2–24 hr | 10 μg/mL cytotoxic | |
| CdSe–MAA, TOPO QDs | Primary rat hepatocytes | 62.5–1,000 μg/mL | 1–8 hr | Cytotoxic: 62.5 μg/mL cytotoxic under oxidative/photolytic conditions
| ||
| QD micelles: CdSe/ZnS QDs in (PEG–PE) and phosphatydilcholine | 5 × 109 QDs/cell (~ 0.23 pmol/cell) | 1.5–3 nL of 2.3 μM QDs injected, ~ 2.1 × 109 to 4.2 × 109 injected QDs/cell | Days | 5 × 109 QDs/cell: cell abnormalities, altered viability and motility
| ||
| CdSe/ZnS amp-QDs, and mPEG QDs | Mice | 200-μL tail vein injection | Injections; ~ 180 nM QD, ~ 20 pmol QD/g animal weight | 15 min cell incubations, 1–133 days | No signs of localized necrosis at the sites of deposition | |
| CdSe/ZnS–DHLA | 400–600 nM | 45–60 min | No effects on cell growth | |||
| Avidin-conjugated CdSe/ZnS QDs | HeLa cells | 0.5–1.0 μM | 15 min | No effect on cell growth, development | ||
| CdSe/ZnS–amphiphilic micelle | Mice | Tail vein injection | 60 μM QD/g animal weight, 1 μM and 20 nM final QD concentration | Not given | Mice showed no noticeable ill effects after imaging | |
| CdSe/ZnS–DHLA QDs | Mice, B16F10 cells | 5 × 104 B16F10 cells with 10 μL QDs (~ 10 pmol), tail vein (iv) injection | 100 μL of B16F10 cells used for tail vein injection, ~ 2 × 105 to 4 × 105 cells injected | 4–6 hr cell incubation, mice sacrificed at 1–6 hr | No toxicity observed in cells or mice | |
| CdSe/ZnS–MUA QDs; QD–SSA complexes | Vero cells | 0.4 mg/mL | 0.24 mg/mL | 2 hr | 0.4 mg/mL MUA/SSA–QD complexes did not affect viability of Vero cells | |
| CdSe/ZnS | HeLa cells | 1 × 106 cells | 10 pmol QDs/1 × 105 cells (~ 10 nM) | 10 days (cell culture) | 10 nM QD had minimal impact on cell survival |